Supplement encyclopedia

Curcumin

Curcumin is a compound found in turmeric and used in concentrated supplements.

Check the conclusions and examine the sources before choosing a supplement.

Main conclusion

What it may offer

  • In healthy adults aged 45–74, taking Longvida for 12 weeks did not improve the ability to hold information in mind and recall events compared with placebo.
  • In the same study, the supplement provided no noticeable advantage in tests of processing speed, attention and control of one’s actions.
  • Two specific curcumin formulations, TS-P1 and CR-033P, may reduce the total number of days with individual cold symptoms. This was the result of taking 150 mg of curcumin daily for 12 weeks in healthy adults in Japan.
  • With TS-P1, participants recorded fewer days of sneezing and runny nose in their diaries than with placebo.

[1] [2]

What was studied

  • One study tested the ability to hold information in mind and recall events, processing speed and attention in healthy middle-aged and older adults.
  • Another 12-week study compared two specific formulations with placebo using self-reported cold symptoms.

[1] [2]

Which forms were considered

  • Curcumin is an individual substance, while curcuminoids and plant extract are mixtures; product mass is not the same as the mass of pure curcumin.
  • The cognitive test study used Longvida, while the cold symptom study used TS-P1 and CR-033P; the formulation’s composition matters for the applicability of the result.

[1] [2] [3]

How to obtain it from food

  • Curcumin is obtained from turmeric, which is used as a spice and added to dishes and curry blends. For a food source, the composition of the product itself matters, not just the mass of the spice.
  • Curcumin content can vary considerably: an analysis of 13 commercial turmeric powders found 0.057% to 2.06% by mass. This variation helps explain why equal amounts of different powders provide different amounts of curcumin.

[1] [2] [3]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Working memory, NIH Toolbox list sortingWorking memory in this test did not differ from placebo.Working memory, list sorting: 17±1→17±1 in both groups, group×time interaction p=0.97.
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.
11 trialCurcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗39 healthy adults aged 45–74
  1. Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗
Episodic memoryEpisodic memory in this test showed no difference from placebo.Picture sequence memory: curcumin 475.1±22.2→516.8±25.6, placebo 487.4±23.6→501.7±25.3; interaction p=0.3.
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.
11 trialCurcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗39 healthy adults aged 45–74
  1. Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗
Processing speedProcessing speed in two tests showed no difference from placebo.Pattern comparison: interaction p=0.5; Trail Making A: p=0.6.
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.
11 trialCurcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗39 healthy adults aged 45–74
  1. Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Memory studyLongvida: 2000 mg of product daily, about 400 mg of curcumin itself, for 12 weeks.
Cold symptom studyTS-P1 or CR-033P: 150 mg of curcumin itself daily for 12 weeks.

Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗
Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study ↗

Forms

Curcumin is an individual molecule; curcuminoids are a mixture; plant extract and product mass are not equivalent to the pure substance. Bioavailability does not prove clinical benefit.

Guidance for each goal

Working memory, NIH Toolbox list sorting1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.

Working memory in this test did not differ from placebo.

Study findings. Working memory in this test did not differ from placebo.

Studied regimenLongvida 2000 mg of product, about 400 mg of curcuminLongvida 2000 mg of product, about 400 mg of curcumin
Duration and population12 weeks39 healthy adults aged 45–74

Comparison with Placebo

Episodic memory1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.

Episodic memory in this test showed no difference from placebo.

Study findings. Episodic memory in this test showed no difference from placebo.

Studied regimenLongvida 2000 mg of product, about 400 mg of curcuminLongvida 2000 mg of product, about 400 mg of curcumin
Duration and population12 weeks39 healthy adults aged 45–74

Comparison with Placebo

Processing speed1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.

Processing speed in two tests showed no difference from placebo.

Study findings. Processing speed in two tests showed no difference from placebo.

Studied regimenLongvida 2000 mg of product, about 400 mg of curcuminLongvida 2000 mg of product, about 400 mg of curcumin
Duration and population12 weeks39 healthy adults aged 45–74

Comparison with Placebo

Executive function1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: No exact CI. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: The specific Longvida formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: 39 people and a battery of outcomes.

Measures of executive function and attention in these tests did not differ from placebo.

Study findings. Measures of executive function and attention in these tests did not differ from placebo.

Studied regimenLongvida 2000 mg of product, about 400 mg of curcuminLongvida 2000 mg of product, about 400 mg of curcumin
Duration and population12 weeks39 healthy adults aged 45–74

Comparison with Placebo

Sum of days with individual symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

TS-P1: the sum of days with individual symptoms was lower than with placebo.

Study findings. TS-P1: the sum of days with individual symptoms was lower than with placebo.

Studied regimenOral TS-P1, 150 mg of curcumin/dayOral TS-P1, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Sum of days with individual symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

CR-033P: the sum of days with individual symptoms was lower than with placebo.

Study findings. CR-033P: the sum of days with individual symptoms was lower than with placebo.

Studied regimenOral CR-033P, 150 mg of curcumin/dayOral CR-033P, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Sum of maximum durations of individual symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

TS-P1: the sum of maximum durations of individual symptoms was lower than with placebo.

Study findings. TS-P1: the sum of maximum durations of individual symptoms was lower than with placebo.

Studied regimenOral TS-P1, 150 mg of curcumin/dayOral TS-P1, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Sum of maximum durations of individual symptoms1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

CR-033P: the sum of maximum durations of individual symptoms was lower than with placebo.

Study findings. CR-033P: the sum of maximum durations of individual symptoms was lower than with placebo.

Studied regimenOral CR-033P, 150 mg of curcumin/dayOral CR-033P, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Sneezing symptom-days1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

TS-P1: participants recorded fewer days of sneezing than with placebo.

Study findings. TS-P1: participants recorded fewer days of sneezing than with placebo.

Studied regimenOral TS-P1, 150 mg of curcumin/dayOral TS-P1, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Runny nose symptom-days1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowPrecision of the estimate: Small groups and broad uncertainty. Consistency of results: No grounds for a separate downgrade. Applicability to the stated group: Self-reported symptoms and a specific formulation. Possible publication bias: No specific data for a separate downgrade. Study methods: Two active arms with a shared control, several outcomes.

TS-P1: participants recorded fewer days of runny nose than with placebo.

Study findings. TS-P1: participants recorded fewer days of runny nose than with placebo.

Studied regimenOral TS-P1, 150 mg of curcumin/dayOral TS-P1, 150 mg of curcumin/day
Duration and population12 weeks99 healthy Japanese adults, 33 in each group

Comparison with Placebo

Safety and limitations

60 healthy people; Turmipure Gold 1000 mg of product versus placebo for 5 weeks: any events 22/30 versus 18/30, without determining causality for individual cases; safety regarding rare events is unknown. DILIN: 10 turmeric-associated cases, 5 hospitalizations, 1 death; median 86 days. There is no denominator for estimating frequency, and the exact causal component has not been established. The safety of concentrated supplements during pregnancy has not been established; food amounts are not equivalent to supplement doses. Data on high doses and infant exposure are limited; an RCT of a multicomponent mixture does not isolate curcumin. A short study in a clinical group does not establish general long-term safety for children. If marked fatigue, nausea, loss of appetite, dark urine or jaundice develops while taking a turmeric or curcumin supplement, stop taking it and seek medical advice. 79 randomized participants with gastrointestinal complaints; Curcugen 500 mg of product versus placebo for 8 weeks, GSRS 2.91→2.10 versus 2.65→2.18, interaction p=0.021. 5 studies in the pooled analysis, different formulations and groups: SMD +0.14 (−0.78; +1.07), I² 90.8%; no convincing overall change. Data from clinical groups do not automatically apply to healthy people and do not establish a replacement for usual care. The risk of liver injury may be higher with high-dose supplements or those with enhanced absorption. People with current or previous liver disease should avoid turmeric or curcumin supplements. Before surgery, tell the surgical team that you take a turmeric or curcumin supplement.

Safety assessment and gastrointestinal tolerance of a novel highly bioavailable turmeric extract formulation: A randomised, double-blind, placebo controlled clinical trial ↗ · Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network ↗ · Turmeric: Usefulness and Safety ↗ · Turmeric - Drugs and Lactation Database (LactMed) ↗ · Curcumin in children with autism spectrum disorder: systemic inflammation, sensory regulation, and gut-brain interaction disorders. A randomized, double-blind, placebo-controlled clinical trial (CURATEA) ↗ · Efficacy of a curcumin extract (Curcugen) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗ · Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis ↗ · Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗ · TGA Medicines containing turmeric or curcumin - risk of liver injury ↗ · Herbal remedies and dietary supplements - Overview | Guy's and St Thomas' NHS Foundation Trust ↗

Interactions

WithEffectActionSource
TamoxifenIn a small study, curcumin without piperine changed endoxifen AUC by −7.7% (the CI includes no change), and curcumin with piperine by −12.4%; the study did not assess the clinical outcome of treatment.Before using a curcumin supplement, discuss it with your treating oncologist.Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
Warfarin and other anticoagulants or antiplatelet medicinesTurmeric in supplements may increase the risk of bleeding; the evidence includes preclinical data and a case report.Discuss the supplement with the doctor managing your treatment before using it.Turmeric | Memorial Sloan Kettering Cancer Center ↗
TacrolimusAn isolated case of an increased tacrolimus level after consuming a large amount of turmeric has been reported.Before using turmeric or curcumin, discuss them with the doctor who prescribed tacrolimus.Turmeric | Memorial Sloan Kettering Cancer Center ↗

Food sources

Curcumin is found in turmeric, but the amount differs between products. The mass of the spice alone does not show the amount of curcumin in a portion.

Curcumin is a component of turmeric, which is used as a spice. The curcumin content of a food portion cannot be equated with the dose of a concentrated supplement.

Turmeric: Usefulness and Safety ↗

Curcumin content differs between products: in an analysis of 13 commercial turmeric powders, the mass fraction was 0.057–2.06%.

Chromatographic evaluation of curcumin content in commercial samples ↗

Ground turmeric Dried, ground turmeric rhizome is used as a spice for flavour and colour.

Turmeric: Usefulness and Safety ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 02 ↗

Rhizome and dishes The rhizome is added to dishes; the composition of a portion depends on the product and recipe.

Turmeric: Usefulness and Safety ↗
Turmeric | Memorial Sloan Kettering Cancer Center ↗

Spice blends Turmeric is an ingredient in curry powder.

Turmeric | Memorial Sloan Kettering Cancer Center ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗randomized controlled trialWorking memory, NIH Toolbox list sorting: Working memory, NIH Toolbox list sorting Episodic memory: Episodic memory Processing speed: Processing speed Executive function: Executive functionWorking memory, NIH Toolbox list sorting: 39 healthy adults aged 45–74 Episodic memory: 39 healthy adults aged 45–74 Processing speed: 39 healthy adults aged 45–74 Executive function: 39 healthy adults aged 45–74Working memory, NIH Toolbox list sorting: Longvida 2000 mg of product, about 400 mg of curcumin; Longvida 2000 mg of product, about 400 mg of curcumin; 12 weeks; comparison: Placebo Episodic memory: Longvida 2000 mg of product, about 400 mg of curcumin; Longvida 2000 mg of product, about 400 mg of curcumin; 12 weeks; comparison: Placebo Processing speed: Longvida 2000 mg of product, about 400 mg of curcumin; Longvida 2000 mg of product, about 400 mg of curcumin; 12 weeks; comparison: Placebo Executive function: Longvida 2000 mg of product, about 400 mg of curcumin; Longvida 2000 mg of product, about 400 mg of curcumin; 12 weeks; comparison: PlaceboWorking memory, NIH Toolbox list sorting: Working memory in this test did not differ from placebo. Episodic memory: Episodic memory in this test showed no difference from placebo. Processing speed: Processing speed in two tests showed no difference from placebo. Executive function: Measures of executive function and attention in these tests did not differ from placebo.
Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study ↗randomized controlled trialSum of days with individual symptoms: Sum of days with individual symptoms Sum of maximum durations of individual symptoms: Sum of maximum durations of individual symptoms Sneezing symptom-days: Sneezing symptom-days Runny nose symptom-days: Runny nose symptom-daysSum of days with individual symptoms: 99 healthy Japanese adults, 33 in each group Sum of maximum durations of individual symptoms: 99 healthy Japanese adults, 33 in each group Sneezing symptom-days: 99 healthy Japanese adults, 33 in each group Runny nose symptom-days: 99 healthy Japanese adults, 33 in each groupSum of days with individual symptoms: Oral TS-P1, 150 mg of curcumin/day; Oral TS-P1, 150 mg of curcumin/day; 12 weeks; comparison: Placebo Sum of days with individual symptoms: Oral CR-033P, 150 mg of curcumin/day; Oral CR-033P, 150 mg of curcumin/day; 12 weeks; comparison: Placebo Sum of maximum durations of individual symptoms: Oral TS-P1, 150 mg of curcumin/day; Oral TS-P1, 150 mg of curcumin/day; 12 weeks; comparison: Placebo Sum of maximum durations of individual symptoms: Oral CR-033P, 150 mg of curcumin/day; Oral CR-033P, 150 mg of curcumin/day; 12 weeks; comparison: Placebo Sneezing symptom-days: Oral TS-P1, 150 mg of curcumin/day; Oral TS-P1, 150 mg of curcumin/day; 12 weeks; comparison: Placebo Runny nose symptom-days: Oral TS-P1, 150 mg of curcumin/day; Oral TS-P1, 150 mg of curcumin/day; 12 weeks; comparison: PlaceboSum of days with individual symptoms: TS-P1: the sum of days with individual symptoms was lower than with placebo. Sum of days with individual symptoms: CR-033P: the sum of days with individual symptoms was lower than with placebo. Sum of maximum durations of individual symptoms: TS-P1: the sum of maximum durations of individual symptoms was lower than with placebo. Sum of maximum durations of individual symptoms: CR-033P: the sum of maximum durations of individual symptoms was lower than with placebo. Sneezing symptom-days: TS-P1: participants recorded fewer days of sneezing than with placebo. Runny nose symptom-days: TS-P1: participants recorded fewer days of runny nose than with placebo.

Sources

Sources
  1. Curcumin supplementation and motor-cognitive function in healthy middle-aged and older adults ↗
  2. Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study ↗
  3. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen ↗
  4. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability ↗
  5. Efficacy of a curcumin extract (Curcugen) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study ↗
  6. Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis ↗
  7. Safety assessment and gastrointestinal tolerance of a novel highly bioavailable turmeric extract formulation: A randomised, double-blind, placebo controlled clinical trial ↗
  8. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network ↗
  9. Turmeric | Memorial Sloan Kettering Cancer Center ↗
  10. Turmeric: Usefulness and Safety ↗
  11. Turmeric - Drugs and Lactation Database (LactMed) ↗
  12. Curcumin in children with autism spectrum disorder: systemic inflammation, sensory regulation, and gut-brain interaction disorders. A randomized, double-blind, placebo-controlled clinical trial (CURATEA) ↗
  13. Efficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
  14. Chromatographic evaluation of curcumin content in commercial samples ↗
  15. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — food group 02 ↗
  16. TGA Medicines containing turmeric or curcumin - risk of liver injury ↗
  17. Herbal remedies and dietary supplements - Overview | Guy's and St Thomas' NHS Foundation Trust ↗